JOHNSON PHARMACARE LIMITED (JOHNPHARMA.BO)
INR 1.19
(-0.84%)
INR 1.19
(-0.84%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | - | 25.26 Million | 32.63 Million | 7.6 Million | - | 9.2 Million |
| Cost of Revenue | - | 20.93 Million | 27.87 Million | 6.74 Million | - | 9.24 Million |
| Gross Profit | - | 4.33 Million | 4.75 Million | 860 Thousand | - | -44.5 Thousand |
| Operating Expenses | 1.95 Million | 2.09 Million | 3.4 Million | 844.13 Thousand | 918.05 Thousand | 64.85 Thousand |
| Selling, General and Administrative Expenses | 1.95 Million | 1.99 Million | 3.3 Million | 844.13 Thousand | 918.05 Thousand | 64.85 Thousand |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | -106 Thousand | -106.5 Thousand | - | - | - |
| Cost and Expenses | 1.95 Million | 23.03 Million | 31.28 Million | 7.58 Million | 918.05 Thousand | 9.3 Million |
| Operating Income | -1.95 Million | 2.23 Million | 1.34 Million | 15.86 Thousand | -918.05 Thousand | -109.35 Thousand |
| Interest Expense | 9000.00 | 8000.00 | 3481.00 | - | - | - |
| Income Tax Expense | -1.96 Million | -379 Thousand | 377.02 Thousand | 4126.00 | -171.86 Thousand | -161.14 Thousand |
| Earnings before Tax | -1.96 Million | -13.29 Million | 1.34 Million | 15.86 Thousand | -918.05 Thousand | -109.35 Thousand |
| Net Income | -1.96 Million | -12.91 Million | 966.56 Thousand | 11.74 Thousand | -918.05 Thousand | -109.35 Thousand |
| Earnings Per Share Basic | -0.00 | -0.02 | 0.00 | - | -0.00 | -0.00 |
| Earnings Per Share Diluted | -0.00 | -0.02 | 0.00 | - | -0.00 | -0.00 |
| Weighted Average Shares Outstanding | 550 Million | 550 Million | 604.99 Million | 549.99 Million | 549.99 Million | 549.99 Million |
| Weighted Average Shares Outstanding (Diluted) | 550 Million | 550 Million | 604.99 Million | 549.99 Million | 549.99 Million | 549.99 Million |
| Gross Margin | - | 0.17 | 0.15 | 0.11 | - | -0.00 |
| EBIT Margin | - | 0.09 | 0.04 | 0.00 | - | -0.01 |
| Profit Margin | - | -0.51 | 0.03 | 0.00 | - | -0.01 |
| EBITDA | -1.95 Million | -13.28 Million | 1.34 Million | 15.86 Thousand | -918.05 Thousand | -109.35 Thousand |
| Earnings Before Tax Margin | - | 0.09 | 0.04 | 0.00 | - | -0.01 |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 399 Thousand | 20 Thousand | 46 Thousand | 18 Thousand | 1.87 Million | 837 Thousand |
| Selling, General and Administrative Expenses | 399 Thousand | 20 Thousand | 46 Thousand | 18 Thousand | 1.87 Million | 837 Thousand |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 399 Thousand | 20 Thousand | 46 Thousand | 18 Thousand | 1.87 Million | 837 Thousand |
| Operating Income | -399 Thousand | -20 Thousand | -46 Thousand | -18 Thousand | -1.87 Million | -837 Thousand |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | - | 39.58 Thousand | -122.08 Thousand | -41.58 Thousand | -54.88 Thousand |
| Earnings before Tax | -399 Thousand | -20 Thousand | -46 Thousand | -18 Thousand | -1.87 Million | -837 Thousand |
| Net Income | -399 Thousand | -20 Thousand | -46 Thousand | -18 Thousand | -1.87 Million | -837 Thousand |
| Earnings Per Share Basic | -0.00 | - | -0.00 | - | -0.00 | -0.00 |
| Earnings Per Share Diluted | -0.00 | - | -0.00 | - | -0.00 | -0.00 |
| Weighted Average Shares Outstanding | 550 Million | 550 Million | 550 Million | 550 Million | 550 Million | 550 Million |
| Weighted Average Shares Outstanding (Diluted) | 550 Million | 550 Million | 550 Million | 550 Million | 550 Million | 550 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -399 Thousand | -20 Thousand | -46 Thousand | -18 Thousand | -1.87 Million | -837 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - | - |
GML
2125
1NBA
MAHAPEXLTD
DRMA
6349